D+Q (Dasatinib + Quercetin) Senolytic
D+
36.5/100
Evidence Summary
D+Q is the original senolytic combination, pioneered by James Kirkland at Mayo Clinic. The concept — selectively killing senescent cells — is compelling, and preclinical data is strong. Human pilot studies (14-20 participants) showed reduced senescent cell markers.
However, no completed Phase 2+ RCT has demonstrated clinical benefit. Dasatinib is a chemotherapy drug with significant side effects. The D+ grade reflects the gap between the elegant theory of senolytics and the thin clinical evidence supporting this specific combination.
However, no completed Phase 2+ RCT has demonstrated clinical benefit. Dasatinib is a chemotherapy drug with significant side effects. The D+ grade reflects the gap between the elegant theory of senolytics and the thin clinical evidence supporting this specific combination.
Safety Considerations
Dasatinib is a tyrosine kinase inhibitor with significant side effects: myelosuppression, fluid retention, QT prolongation, pleural effusions. Pulsed dosing (2 days per month) reduces but does not eliminate risk. NOT a casual supplement — requires physician supervision.
Evidence Signals (0)
Products Containing D+Q (Dasatinib + Quercetin) Senolytic
No commercial products are currently listed for this molecule.
Regulatory Intelligence
This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.